Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? - PubMed (original) (raw)

Multicenter Study

doi: 10.1634/theoncologist.2011-0445. Epub 2012 Jun 6.

Giovanni Cioffi, Silvia Frattini, Edda Lucia Simoncini, Pompilio Faggiano, Lidia Boccardi, Giovanni Pulignano, Agnese Maria Fioretti, Francesco Giotta, Chiara Lestuzzi, Nicola Maurea, Silvia Sabatini, Luigi Tarantini; Italian Cardio-Oncological Network

Affiliations

Multicenter Study

Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?

Stefano Oliva et al. Oncologist. 2012.

Abstract

Background: Adjuvant trastuzumab therapy improves the outcome of patients with early breast cancer (EBC) and overexpression of human epidermal growth factor receptor 2 (HER2). However, it is potentially cardiotoxic. This study aims to evaluate the relationship between the use of angiotensin-converting enzyme inhibitors/receptor blockers (ACEi/ARBs) and/or β-blockers and development of heart failure (HF) and/or left ventricular dysfunction during 1 year of adjuvant trastuzumab therapy.

Methods: A total of 499 women receiving adjuvant trastuzumab therapy for EBC entered in a multicenter registry and were divided into four subgroups according to treatment with ACEi/ARBs and/or β-blockers. Occurrence of HF and decrease of left ventricular ejection fraction (LVEF; minimum 10 percentage points) were recorded.

Results: HF occurred in 2% of patients who did not take either ACEi/ARBs or β-blockers, 8% of patients receiving ACEi/ARBs alone, 8% receiving β-blockers alone (p = .03), and 19% receiving both medications (p < .01). The prevalence of patients with LVEF that decreased by at least 10 percentage points was similar in all groups. Combined ACEi/ARBs and β-blocker therapy was independently associated with hypertension and a significant reduction of LVEF from baseline to 3-month evaluation. The use of ACEi/ARBs alone or β-blockers alone was predicted only by hypertension. Combined therapy of ACEi/ARBs plus β-blockers predicted LVEF recovery from the 3-month to 12-month evaluation.

Conclusions: In clinical practice, the degree of hypertension and decrease in LVEF during the first 3 months of adjuvant trastuzumab therapy for EBC are associated with the use of ACEi/ARBs and β-blockers. The combined use of these two medications is associated with a recovery of LVEF during months 3-12 of adjuvant trastuzumab therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors indicated no financial relationships.

Figures

Figure 1.

Figure 1.

Prevalence of new-onset symptoms of heart failure and reduction in left ventricular ejection fraction >10 percentage points during 1-year follow-up according to the pharmacological treatment with β-blockers and/or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; LVEF, left ventricular ejection fraction.

Figure 2.

Figure 2.

Kaplan-Meier plot of 1-year survival free from cardiotoxic events occurring at any time during the follow-up period according to medical treatment. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-blocker.

Figure 3.

Figure 3.

Trend of left ventricular ejection fraction in the study subgroups during 1-year trastuzumab therapy expressed as mean absolute values (upper panel) and change from baseline echocardiographic evaluation (bottom panel). Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-blocker; LVEF, left ventricular ejection fraction.

References

    1. Ferlay J, Shin HR, Bray F, et al. Lyon, France: International Agency for Research on Cancer; 2010. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10.
    1. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008;31:459–467. - PubMed
    1. de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indium trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanism of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43:2046–2051. - PubMed
    1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. - PubMed
    1. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459–465. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources